Dronedarone, marketed by Sanofi-Aventis as Multaq, is a prescription medication used to treat cardiac arrhythmias (irregular heartbeat).
Multaq treats abnormal heart rhythms, such as arterial fibrillation or arterial flutter. Multaq was approved by the FDA on July 2, 2009. Within one year, almost 500,000 Multaq prescriptions had been dispensed in the United States.
On January 4, 2011, the Food & Drug Administration alerted healthcare professionals to rare cases of severe liver damage associated with the use of Multaq. Symptoms of severe liver damage include stomach pain, weakness, shortness of breath, redness, difficulty breathing, rashes, diarrhea, rapid weight gain, and slowed heartbeat.
The FDA has received numerous reports of liver injury and liver failure in patients taking Multaq. In fact, two documented cases of acute liver failure led to liver transplants. The two cases involved women approximately 70 years old, with no history of liver problems. Within 4-6 months of taking Multaq, both women developed acute hepatic failure, requiring transplantation.
Help If You've Been Injured by Multaq
At O'Hanlon, McCollom & Demerath, our attorneys understand that your liver injuries may not be your fault – instead, possibly a dangerous side effect of Multaq. Our expertise and experience, combined with our highly trained staff, make us uniquely well equipped to handle even the most complex product liability cases.
If you suspect you've had a Multaq injury such as acute liver failure or a liver transplant, and need to talk to a seasoned team of professionals, please contact us immediately for a free consultation.